In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
Abstract Zanubrutinib is a highly selective, potent, orally available, targeted covalent inhibitor (TCI) of Bruton's tyrosine kinase (BTK). This work investigated the in vitro drug metabolism and transport of zanubrutinib, and its potential for clinical drug-drug interactions (DDIs). Phenotypin...
Saved in:
Main Authors: | Heather Zhang (Author), Ying C. Ou (Author), Dan Su (Author), Fan Wang (Author), Lai Wang (Author), Srikumar Sahasranaman (Author), Zhiyu Tang (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
by: Rhodes JM, et al.
Published: (2021) -
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
by: Lucie Čermáková, et al.
Published: (2022) -
Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
by: Kun Wang, et al.
Published: (2021) -
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
by: Holger Scheible, et al.
Published: (2021) -
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
by: Sibel Ucpinar, et al.
Published: (2023)